Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM)

Jennifer J. Wilkes, MDMSCE, Gary H. Lyman, MD MPH, David R Doody, MS, Shasank R Chennupati, PharmD, MPH, Laura Becker, MS, Pamela E Morin, Lena E. Winestone, MD MSHP, Henry (Joe) Henk, PhD, Eric J Chow, MD MPH

Blood (2019) 134 (Supplement_1): 4753.

https://doi.org/10.1182/blood-2019-124106

Published: 2019

Journal Articles

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Massimiliano Bonifacio, MD, Mario Tiribelli, Gianni Binotto, MD, Maria Cristina Miggiano, Marco Basso, Elisabetta Calistri, Luigi Scaffidi, MD, Rossella Stella, Luca Frison, Roberto Sartori, Marco Ruggeri, Gianpietro Semenzato, Renato Fanin, Mauro Krampera

Blood (2019) 134 (Supplement_1): 5909.

https://doi.org/10.1182/blood-2019-131272

Published: 2019

Journal Articles

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Renato Torrescasana Centrone, Marcelo Bellesso, MD, Rodrigo Santucci Silva, MD, Eliseo J. Sekiya, MD, Milton A. F. Aranha, MD, Isabel Bonafe, Daniela Ferreira Dias, MD, Adelson Alves, MD

Blood (2019) 134 (Supplement_1): 5847.

https://doi.org/10.1182/blood-2019-128629

Published: 2019

Journal Articles

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Lydia Benitez, PharmD, Anthony J. Perissinotti, PharmD, Caitlin R. Rausch, PharmD, Jeff Klaus, PharmD, Stephen Michael Clark, PharmD, Michael Filtz, PharmD, Kelley L Ratermann, PharmD, Carissa F. Treptow, PharmD, Shawn Griffin, PharmD, Marissa Olson, PharmD, Mallory Crain, PharmD, Kristen Pettit, MD, Patrick W. Burke, MD, Dale L. Bixby, MD, Bernard Lawrence Marini, PharmD

Blood (2019) 134 (Supplement_1): 2639.

https://doi.org/10.1182/blood-2019-122189

Published: 2019

Journal Articles

Response and Survival in Newly Diagnosed Multiple Myeloma Patients Treated with Cybord Regimen Using Generic Bortezomib — Data from Two Centres from India

Neeraj Sidharthan, MDDM, Akhila Sivadas, Pharm D, Anup Joseph Devasia, MD DM, Uday Prakash Kulkarni, MD DM, Remya Sudevan, MBBS MPH, Keechilat Pavithran, MD DM, FRCP, Raghuveer Prabhu, MBBS, MD DM, Rema Ganapathy, MBBS DNB, Arun Philip, MDDM, Wesley Jose, MDDNB, Manoj Unni, MDDM, Anu Korula, MD DM, Nisham PN, MD DM, Aby Abraham, MD DM, Alok Srivastava, MD, Vikram Mathews, MD DM, Biju George, MDDM

Blood (2017) 130 (Supplement 1): 5398.

https://doi.org/10.1182/blood.V130.Suppl_1.5398.5398

Published: 2017

Journal Articles

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Lu Yu, MD, Qian Jiang, MD

Blood (2017) 130 (Supplement 1): 1605.

https://doi.org/10.1182/blood.V130.Suppl_1.1605.1605

Published: 2017

Journal Articles

Out-of-Pocket (OOP) Costs Associated with Tyrosine Kinase Inhibitors (TKIs) Used for the Treatment of US Patients Diagnosed with Chronic Myeloid Leukemia (CML): A US Retrospective Claims Analysis

Ruth Kim, Deepa Malhotra, Timothy Bell, Fiona An, MD, Jack Mardekian

Blood (2017) 130 (Supplement 1): 2123.

https://doi.org/10.1182/blood.V130.Suppl_1.2123.2123

Published: 2017

Journal Articles

Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia

Iman Aboudalle, MD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, Maro Ohanian, DO, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2906.

https://doi.org/10.1182/blood.V130.Suppl_1.2906.2906

Published: 2017

Journal Articles

The Comparison of Efficacy Between Generic and Branded Imatinib in Achievement of Overall Survival and Cytogenetic Responses in CML Patients in Bosnia and Herzegovina

Amina Kurtovic Kozaric, PhD, Erna Islamagic, Jerald P. Radich, MD, Emina Suljovic Hadzimesic, MD MA, Azra Hasic, MBBS, MA, Sabira Kurtovic, MD

Blood (2016) 128 (22): 5451.

https://doi.org/10.1182/blood.V128.22.5451.5451

Published: 2016

Journal Articles

Survival Outcome of Imatinib Mono Therapy in Chronic Phase Chronic Myeloid Leukemia - a Single Center Experience in Belorus

Janna Kozich, MD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD

Blood (2016) 128 (22): 5452.

https://doi.org/10.1182/blood.V128.22.5452.5452

Published: 2016

Journal Articles

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

Vasily Shuvaev, MD, Mikhail Fominykh, MD, Vera Udaleva, MD, Irina I Zotova, MD, Regina Golovchenko, MD PhD, Dzhariyat Shikhbabaeva, MD, Irina Martynkevich, DSc, Lyudmila Martynenko, Marina Ivanova, MD PhD, Natalya Tsybakova, PhD, Ekaterina Motyko, PhD, Lyubov Polushkina, MD, Nadezhda Potikhonova, MD PhD, Sophya Tyranova, MD PhD, Marina Zenina, MD PhD, Kudrat Abdulkadyrov, MD PhD

Blood (2016) 128 (22): 5441.

https://doi.org/10.1182/blood.V128.22.5441.5441

Published: 2016

Journal Articles

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

Blood (2016) 128 (22): 5442.

https://doi.org/10.1182/blood.V128.22.5442.5442

Published: 2016

Journal Articles

Imatinib Generics in Treatment of Chronic Myeloid Leukemia; A Prospective Observation in Large Cohort of Patients from Polish (PALG) Imatinib Generics Registry

Tomasz Sacha, Joanna Gora-Tybor, Monika Szarejko, MD PhD, Grażyna Bober, MD, Olga Grzybowska-Izydorczyk, Joanna Niesiobędzka-Krężel, MD, Marek Dudziński, MD, Ewa Wasilewska, MD PhD, Krzysztof Myśliwiec, MD, Justyna Gil, MD PhD, Michał Gniot, MD PhD, Iwona Pietkun, MD, Ewa Mędraś, MD PhD, Joanna Wącław, MD, Krzysztof Giannopoulos

Blood (2016) 128 (22): 629.

https://doi.org/10.1182/blood.V128.22.629.629

Published: 2016

Journal Articles

Strategies that delay or prevent the timely availability of affordable generic drugs in the United States

Gregory H. Jones, Michael A. Carrier, Richard T. Silver, Hagop Kantarjian

Blood (2016) 127 (11): 1398–1402.

https://doi.org/10.1182/blood-2015-11-680058

Published: 2016

Journal Articles

The Efficacy and Tolerability of Generic of Imatinib in a Very Specific Group of Chronic Myeloid Leukemia (CML)

Monika Conchon, MD PhD

Blood (2015) 126 (23): 5151.

https://doi.org/10.1182/blood.V126.23.5151.5151

Published: 2015

Journal Articles

Generic Intravenous Busulfan in Hematopoietic Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring

Ezhil Pavai Mohanan, MSc, Shareen Stella Backia Royan, BSc, John C Panetta, PhD, Fouzia Nambiathayil Abubacker, DM, Anu Korula, MD DM, Aby Abraham, MD DM, Auro Viswabandya, MD DM, Biju George, DM, Alok Srivastava, MD FRACP, Vikram Mathews, DM, Poonkuzhali Balasubramanian, PhD

Blood (2015) 126 (23): 4322.

https://doi.org/10.1182/blood.V126.23.4322.4322

Published: 2015

Journal Articles

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

Richard A. Larson, Rena Conti, PhD, William V. Padula, PhD, Jane F. Apperley, Michele Baccarani, MD, Ekkehard Eigendorff, MD, Francois Guilhot, MD, Joelle Guilhot, PhD, Francois-Xavier Mahon, MD PhD, Giovanni Martinelli, MD, Jiri Mayer, Prof., MD PhD, Martin C. Mueller, Dietger Niederwieser, MD, Susanne Saussele, MD, Charles A. Schiffer, MD, Richard T. Silver, MD, Bengt Simonsson, MD PhD, Rudiger Hehlmann, MD

Blood (2014) 124 (21): 738.

https://doi.org/10.1182/blood.V124.21.738.738

Published: 2014

Journal Articles

"Hu thal" : A Survey of North American, Indian and Thai Hematologists Regarding Hydroxyurea Use in Thalassemia

Ravi Shah, MD, Vip Viprakasit, MD D.Phil (Oxon), Amita Trehan, MD, Nicola A. Wright, MD FRCPC

Blood (2014) 124 (21): 4036.

https://doi.org/10.1182/blood.V124.21.4036.4036

Published: 2014

Journal Articles

Generic Imatinib in a Patients with Chronic Myeloid Leukemia in Chronic Phase- a Single Centre Experience

Ivana M Urosevic, MD PhD, Marina Dokic, Ivanka Savic, Aleksandar Savic, Ivana Milosevic, MDPhD, Nebojsa Rajic, Nebojsa V. Andjelkovic, PhD MD, Borivoj Sekulic, Nada V Vlaisavljevic, MD

Blood (2014) 124 (21): 5533.

https://doi.org/10.1182/blood.V124.21.5533.5533

Published: 2014

Journal Articles

Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs

Grigoris T Gerotziafas, Mouna Sassi, Vassiliki Galea, Jawed Fareed, PhD, Jeanine M. Walenga, PhD, Ismail Elalamy

Blood (2010) 116 (21): 3334.

https://doi.org/10.1182/blood.V116.21.3334.3334

Published: 2010

NARROW

Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM)

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Pharmacoeconomic Analysis of the Real World Treatment of Chronic Myeloid Leukemia in Chronic Phase of a Brazilian Private Institution Considering the Use of Generic Drugs and Eventual Discontinuation of Treatment

Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML

Response and Survival in Newly Diagnosed Multiple Myeloma Patients Treated with Cybord Regimen Using Generic Bortezomib — Data from Two Centres from India

Variables Associated with Patient-Reported Symptoms in Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Out-of-Pocket (OOP) Costs Associated with Tyrosine Kinase Inhibitors (TKIs) Used for the Treatment of US Patients Diagnosed with Chronic Myeloid Leukemia (CML): A US Retrospective Claims Analysis

Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia

The Comparison of Efficacy Between Generic and Branded Imatinib in Achievement of Overall Survival and Cytogenetic Responses in CML Patients in Bosnia and Herzegovina

Survival Outcome of Imatinib Mono Therapy in Chronic Phase Chronic Myeloid Leukemia - a Single Center Experience in Belorus

The Devil Is Not As Black As He Is Painted - 3-Year Experience of Treating Newly Diagnosed CML Patients with Imatinib Generics

It Is Safe to Change Horses in the Midstream - 3-Year Experience of Treating CML Patients with Imatinib Generics

Imatinib Generics in Treatment of Chronic Myeloid Leukemia; A Prospective Observation in Large Cohort of Patients from Polish (PALG) Imatinib Generics Registry

Strategies that delay or prevent the timely availability of affordable generic drugs in the United States

The Efficacy and Tolerability of Generic of Imatinib in a Very Specific Group of Chronic Myeloid Leukemia (CML)

Generic Intravenous Busulfan in Hematopoietic Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring

What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?

"Hu thal" : A Survey of North American, Indian and Thai Hematologists Regarding Hydroxyurea Use in Thalassemia

Generic Imatinib in a Patients with Chronic Myeloid Leukemia in Chronic Phase- a Single Centre Experience

Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only